NCT02140554

A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Genetix Biotherapeutics Inc. · Industry
• Sex: All
• Age: 12 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This is a non-randomized, open label, multi-site, single dose, Phase 1/2 study in approximately 50 adults and adolescents with severe SCD. The study will evaluate hematopoietic stem cell and progenitor stem cell (collectively referred to as hematopoietic stem and progenitor cells or HSPCs) transplantation using lovo-cel.

Detailed description

Subject participation for this study will be 2 years post-transplant. Subjects who enroll in this study will be asked to participate in a subsequent long-term follow up study that will monitor the safety and efficacy of the treatment they receive for an additional 13 years for a total of 15 years post-drug product infusion.

Conditions

• Sickle Cell Disease

Interventions

Type	Name	Description
GENETIC	lovo-cel	lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.

Timeline

• Start date: 2015-02-02
• Primary completion: 2023-07-31
• Completion: 2024-01-30
• First posted: 2014-05-16
• Last updated: 2025-03-14
• Results posted: 2024-10-08

Locations

11 sites across 1 country: United States